

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

During the scoping process it was highlighted by the company that treatment of acanthamoeba keratitis is mainly provided by specialist centres. Therefore, there may be a delay in treatment dependent on location in England and ability to travel to access treatment.

The committee reviewed the above issue during the meeting but did not consider it an equalities issue that it could address through its recommendations.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

N/A

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A

7. Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?

Yes, section 3.23 of the draft guidance

Approved by Associate Director (name):Richard Diaz.....

Date: 6 Feb 2026